The Devastating Impact of Missing Puberty - James Linehan (#5)
James Linehan was born with hypogonadism and grew up unable to go through natural puberty — giving him a unique and unsettling perspective on what gender clinics have been offering British children. As NHS England withdraws puberty blockers following the Cass Review, his account of emotional vulnerability, social stunting and lasting health consequences puts human flesh on what was for years a policy abstraction. This episode is essential listening for anyone trying to understand what was at stake when British institutions chose to medicalise gender-questioning youth.
James Linehan did not choose to miss puberty. Born with hypogonadism, a medical condition in which the body fails to produce the hormones necessary for sexual development, he spent his adolescence watching his peers grow into adulthood while he remained physically and emotionally frozen in a kind of extended childhood. His experience was not the result of any ideological intervention — yet it placed him in precisely the same biological territory that gender clinics across Britain were deliberately creating for thousands of gender-questioning children over the past two decades. In conversation with Stella O'Malley, Mia Hughes and Dr Bret Alderman, Linehan describes how the absence of puberty left him acutely vulnerable. He was easier to manipulate, socially isolated, and unable to develop the emotional resilience that comes with hormonal maturation. These are not abstract theoretical risks — they are lived consequences that took him decades to understand and articulate. His account gives urgent, concrete weight to the concerns raised by clinicians and researchers who argued, often against fierce opposition, that puberty is not a neutral process that can be safely paused without cost. The episode confronts one of the most contested claims in recent British medical debate: that puberty blockers are reversible. Linehan challenges this directly from personal experience. His own fertility was permanently affected. The developmental windows that puberty opens — for bone density, brain maturation, reproductive capacity — do not simply reopen on demand once hormones are eventually introduced. His case illustrates that the consequences of suppressed puberty are not confined to the years of treatment; they compound across an entire lifetime. The release of this episode in early 2025 falls within a moment of profound reckoning in the United Kingdom. The Cass Review, published in April 2024, concluded that the evidence base for prescribing puberty blockers to gender-distressed young people was remarkably weak. NHS England subsequently banned their use for this purpose, and the Gender Identity Development Service at the Tavistock — once the flagship of British youth gender medicine — has been closed. Families, clinicians and policymakers are now confronting what was sanctioned for years, and at what cost. Linehan's testimony, from someone who has lived with the consequences of absent puberty throughout his adult life, is precisely the kind of first-person evidence that was conspicuously missing from that clinical debate. What distinguishes this conversation is that Linehan brings no ideological agenda. He is not a campaigner. He is a man who experienced, involuntarily, something that clinics were prescribing to children as a medical intervention. His observations about docility — about the way suppressed puberty left him more compliant and less capable of advocating for himself — carry serious implications for how Britain ought to evaluate the consent processes used in gender medicine, and whether children held in a state of hormonally induced developmental suspension were ever genuinely equipped to make informed decisions about what came next.
